查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1318010

糖尿病藥物市場：按藥物類型（注射劑、口服藥物）、用途（1 型糖尿病、2 型糖尿病）- 2023-2030 年全球預測

Diabetes Drugs Market by Drug Type (Injectable Drug, Oral Drug), Application (Type 1 Diabetes, Type 2 Diabetes) - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2023 年，全球抗糖尿病藥物市場規模將達到 631.1 億美元，年複合成長率為 6.97%，預計到 2030 年將成長至驚人的 1,013.2 億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球糖尿病治療市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發地區、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.全球糖尿病藥物市場規模及預測為何？

2.在預測期內，COVID-19 對全球糖尿病治療藥物市場的阻礙因素和影響為何？

3. 在預測期內，全球糖尿病藥物市場需要投資哪些產品/細分市場/用途/領域？

4.你們在全球糖尿病藥物市場的競爭策略是什麼？

5. 全球糖尿病藥物市場的技術趨勢和法律規範是什麼？

6.全球糖尿病藥物市場主要廠商的市佔率為何？

7. 哪些型態和策略性舉措被認為適合進入全球糖尿病藥物市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 促進因素
      • 糖尿病盛行率增加
      • 由於不健康的用餐和久坐的生活方式導致肥胖增加
      • 健康意識項目的數量正在迅速增加
    • 抑制因素
      • 有時會出現藥物副作用
    • 機會
      • 製藥商在糖尿病治療方面的進展
      • 加大醫療衛生投入和醫療衛生基礎建設
    • 任務
      • 患者缺乏藥物可用性意識
  • 市場趨勢
  • COVID-19 的累積影響
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範
  • 客戶客製化

第6章 糖尿病藥物市場：依藥物類型

  • 介紹
  • 注射藥物
    • 作為一部分
    • 艾塞那肽
    • 甘精胰島素
    • 胰島素
    • 來拉魯肽
    • 普蘭林勝肽
  • 口腔醫學
    • α-葡萄糖苷酶抑制劑
    • 雙胍類
    • DPP-4抑制劑
    • 美格列奈類和D-苯丙胺酸衍生物
    • 磺醯脲類
    • 噻唑烷二酮

第7章 糖尿病藥物市場：依用途

  • 介紹
  • 1型糖尿病
  • 2型糖尿病

第8章 北美和南美糖尿病藥物市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章 亞太糖尿病藥物市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲糖尿病藥物市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭形勢

  • FPNV定位矩陣
  • 市佔率分析：主要企業
  • 競爭情境分析：主要企業

第12章上市公司名單

第13章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-434CCDA051CA

The Global Diabetes Drugs Market is forecasted to grow significantly, with a projected USD 63.11 billion in 2023 at a CAGR of 6.97% and expected to reach a staggering USD 101.32 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Diabetes Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Diabetes Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Type, market is studied across Injectable Drug and Oral Drug. The Injectable Drug is further studied across Aspart, Exenatide, Glargine, Insulin, Leraglutide, and Pramlintide. The Oral Drug is further studied across Alpha-Glucosidase Inhibitors, Biguanides, DPP-4 Inhibitors, Meglitinides & D-Phenylalanine Derivatives, Sulfonylureas, and Thiazolidinediones. The Oral Drug is projected to witness significant market share during forecast period.

Based on Application, market is studied across Type 1 Diabetes and Type 2 Diabetes. The Type 2 Diabetes is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Diabetes Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Diabetes Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Diabetes Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Diabetes Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Diabetes Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Diabetes Drugs Market?

6. What is the market share of the leading vendors in the Global Diabetes Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Diabetes Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Diabetes Drugs Market, by Drug Type, 2022 vs 2030
  • 4.3. Diabetes Drugs Market, by Application, 2022 vs 2030
  • 4.4. Diabetes Drugs Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in prevalence of diabetes disease
      • 5.1.1.2. Rise in obesity coupled with unhealthy diets and sedentary lifestyles
      • 5.1.1.3. Surge in the number of programs to create health awareness
    • 5.1.2. Restraints
      • 5.1.2.1. Side-effects of drugs in certain cases
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in diabetic medications by pharmaceutical manufacturers
      • 5.1.3.2. Rising investment in healthcare and development of healthcare infrastructure
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness among patients towards the availability of drugs
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Diabetes Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Injectable Drug
    • 6.2.1. Aspart
    • 6.2.2. Exenatide
    • 6.2.3. Glargine
    • 6.2.4. Insulin
    • 6.2.5. Leraglutide
    • 6.2.6. Pramlintide
  • 6.3. Oral Drug
    • 6.3.1. Alpha-Glucosidase Inhibitors
    • 6.3.2. Biguanides
    • 6.3.3. DPP-4 Inhibitors
    • 6.3.4. Meglitinides & D-Phenylalanine Derivatives
    • 6.3.5. Sulfonylureas
    • 6.3.6. Thiazolidinediones

7. Diabetes Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Type 1 Diabetes
  • 7.3. Type 2 Diabetes

8. Americas Diabetes Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Diabetes Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Diabetes Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. DIABETES DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETES DRUGS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2030 (%)
  • FIGURE 5. DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
  • FIGURE 6. DIABETES DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. DIABETES DRUGS MARKET DYNAMICS
  • FIGURE 8. DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES DIABETES DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. DIABETES DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. DIABETES DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. DIABETES DRUGS MARKET SIZE, BY ASPART, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. DIABETES DRUGS MARKET SIZE, BY LERAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. DIABETES DRUGS MARKET SIZE, BY PRAMLINTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 14. DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. DIABETES DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. DIABETES DRUGS MARKET SIZE, BY MEGLITINIDES & D-PHENYLALANINE DERIVATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES DIABETES DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY INJECTABLE DRUG, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY ORAL DRUG, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 193. DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 194. DIABETES DRUGS MARKET LICENSE & PRICING